NTN4

NTN4 (Netrin-4) is a secreted glycoprotein that functions as a ligand-sequestering tumor suppressor and a context-dependent signaling molecule in neural and inflammatory biology. NTN4 directly binds Wnt ligands to attenuate Wnt signaling, and loss of NTN4 in mice accelerates tumor onset, progression, and metastasis; its expression is governed by distal enhancer elements regulated by GATA3 and breast cancer risk-associated SNPs (rs11836367, rs61938093), as well as by miR-210 downstream of TNF-α/NF-κB/HIF-1α signaling (PMID:35687692, PMID:32871102, PMID:38175202). NTN4 suppresses epithelial-mesenchymal transition markers (N-cadherin, vimentin) and inhibits cell migration and invasion in breast cancer cells, while in endometrial cancer it binds integrin β1 to activate FAK/SRC/c-MYC signaling and maintain cancer stemness (PMID:27840993, PMID:38164180). Beyond cancer, recombinant NTN4 promotes neurite outgrowth in human sensory neurons, induces pro-inflammatory cytokines (IL-6, IL-8) and chemokines in synovial fibroblasts, and stimulates MMP-3 production in tenocytes as part of a TNF-α/NTN4/MMP-3 axis implicated in extracellular matrix remodeling (PMID:40136644, PMID:40688916).

1. 2014 Low

   Computational and correlative evidence first linked miR-20a to post-transcriptional suppression of NTN4 in endometriosis, raising the question of how NTN4 expression is regulated by miRNAs.

   Evidence Computational target prediction and qRT-PCR expression correlation in patient endometriosis tissues

   PMID:24972566

   Open questions at the time

   • No direct reporter assay or functional rescue to confirm miR-20a binding to NTN4 3′UTR
   • Mechanism by which NTN4 loss contributes to endometriosis pathology undefined
   • Not independently replicated
2. 2016 Medium

   Reciprocal gain- and loss-of-function experiments established NTN4 as an inhibitor of EMT, migration, and invasion in breast cancer, defining its cellular anti-metastatic function.

   Evidence Overexpression and siRNA knockdown in MDA-MB-231 and Hs578T cells with migration/invasion assays and Western blot for N-cadherin and vimentin

   PMID:27840993

   Open questions at the time

   • Receptor mediating anti-EMT activity not identified
   • No in vivo validation of EMT suppression
   • Downstream signaling pathway not mapped
3. 2020 High

   Identification of a causal enhancer variant (rs61938093) that physically contacts the NTN4 promoter established the regulatory architecture controlling NTN4 expression and linked reduced NTN4 to increased breast tumor growth in vivo.

   Evidence Chromatin conformation capture, enhancer reporter assay, NTN4 knockdown with in vitro proliferation and xenograft tumor growth assays

   PMID:32871102

   Open questions at the time

   • Transcription factors mediating enhancer activity at this variant not fully characterized
   • Whether enhancer loss phenocopies NTN4 coding deletion not tested
4. 2022 High

   Direct binding of NTN4 to Wnt ligands revealed its molecular mechanism as a Wnt pathway antagonist, while mouse knockout confirmed its in vivo tumor-suppressive role and a second enhancer SNP (rs11836367) was linked to GATA3-dependent NTN4 upregulation.

   Evidence Co-binding assay of NTN4 with Wnt ligands, CRISPR enhancer editing, mouse NTN4 knockout with tumor and metastasis phenotyping, GATA3 binding assays

   PMID:35687692

   Open questions at the time

   • Specificity for individual Wnt family members not fully delineated
   • Structural basis of NTN4–Wnt interaction unknown
   • Whether Wnt sequestration fully accounts for tumor suppression or additional receptors contribute
5. 2024 Medium

   NTN4 was shown to bind integrin β1 and activate FAK/SRC/c-MYC to sustain cancer stemness in endometrial cancer, revealing a pro-tumorigenic receptor-mediated axis distinct from its Wnt-sequestering tumor-suppressive role.

   Evidence Co-immunoprecipitation of NTN4 with integrin β1, FAK/SRC pharmacological inhibition, sphere-forming and in vivo tumorigenicity assays in endometrial cancer cells

   PMID:38164180

   Open questions at the time

   • NTN4–integrin β1 binding not validated by structural or biophysical reconstitution
   • Context determining whether NTN4 acts as tumor suppressor versus stemness promoter not resolved
   • EXOSC5-dependent NTN4 upregulation mechanism not defined
6. 2024 Medium

   The TNF-α/NF-κB/HIF-1α/miR-210 axis was identified as a direct post-transcriptional silencer of NTN4 in the tumor microenvironment, explaining how macrophage-derived signals suppress NTN4 to promote cancer cell migration.

   Evidence Macrophage–cancer cell co-culture, miR-210 mimic/inhibitor transfection, luciferase 3′UTR reporter with miR-210 binding site mutation, neutralizing antibodies and pharmacological inhibitors in gastric cancer cells

   PMID:38175202

   Open questions at the time

   • Whether miR-210-mediated NTN4 suppression is relevant in non-gastric cancer contexts untested
   • Quantitative contribution of miR-210 versus other NTN4-targeting miRNAs not compared
7. 2025 Medium

   Functional assays with recombinant NTN4 demonstrated its dual role outside cancer: promoting neurite outgrowth in sensory neurons and inducing pro-inflammatory cytokine/chemokine production in synovial fibroblasts and MMP-3 in tenocytes, linking NTN4 to neural development and tissue inflammation/ECM remodeling.

   Evidence Recombinant NTN4 treatment of iPSC-derived sensory neurons (neurite assay), OA synovial fibroblasts (ELISA), and rat tenocytes (qRT-PCR/ELISA) with TNF-α stimulation

   PMID:40136644 PMID:40688916

   Open questions at the time

   • Receptor(s) mediating NTN4 effects in neurons and fibroblasts not identified
   • Signaling pathways downstream of NTN4 in non-cancer cell types not mapped
   • In vivo relevance of NTN4 in joint inflammation and tendon repair not established

• Key unresolved questions include the structural basis of NTN4–Wnt and NTN4–integrin β1 interactions, the determinants of context-dependent tumor-suppressive versus stemness-promoting activity, the receptor(s) mediating NTN4 signaling in neurons and fibroblasts, and the in vivo contribution of NTN4 to inflammatory joint and tendon pathology.
• No crystal/cryo-EM structure of NTN4 or its ligand complexes
• Tissue-specific receptor utilization logic unknown
• No genetic models for NTN4 in inflammatory or neuronal phenotypes beyond cancer